NTG Nordic Transport Group A/S – Q3 2025 Conference Call
October 10, 2025 04:00 ET Â | Source: NTG Nordic Transport Group A/S…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025,…
ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook
Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V.…
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders Annual General Meeting of September 30, 2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General…
ZETADISPLAY AB (publ) INTERIM REPORT 1 APRIL 30 JUNE 2025 (Q2)
Q2 Interim report April – June 2025 for ZetaDisplay AB (publ) is…
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
ASM announces completion of share buyback program
Almere, The NetherlandsJuly 28, 2025, 5:45 p.m. CET ASM International N.V. (Euronext…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…